Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated re-irradiation plus bevacizumab versus bevacizumab alone for recurrent glioblastoma
ChiCTR2000035881Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in glioblastoma (GBM) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Progression-free survival rate. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2000035881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035881.